サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1179914

コンジュゲートワクチンの世界市場-2022-2029

Global Conjugate Vaccine Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
コンジュゲートワクチンの世界市場-2022-2029
出版日: 2023年01月05日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場の概要

コンジュゲートワクチンの世界市場規模は、予測期間（2022-2029年）にCAGR9.5％で成長すると推定されます。

コンジュゲートワクチンとは、強い抗原をキャリアとして弱い抗原を結合させ、弱い抗原に対する免疫系の反応を高めるサブユニットワクチンのことです。感染症に対するコンジュゲートワクチンがあります。細菌やウイルスの中には、免疫系を回避するための多糖類の被膜を持つものがあります。免疫系が未熟な場合、これらの細菌を認識することができるのは、これらのワクチン接種が免疫と反応を引き出すことで固有の多糖体被膜と生物を結びつけるからです。髄膜炎予防のための髄膜炎菌ワクチン、インフルエンザ菌b型（Hib）ワクチン、肺炎球菌ワクチンなどがコンジュゲートワクチンの一例です。

市場力学

髄膜炎菌コンジュゲートワクチンに対する認可の拡大、肺炎球菌ワクチンや髄膜炎菌ワクチンの開発・導入のための主要プレイヤーの増加、ワクチン接種プログラムに関する意識の高まりなどが、予測期間において市場を牽引する要因となっています。

コンジュゲートワクチンのFDA承認の増加は、市場の成長を促進すると予想されます。

2022年12月28日、ファイザー株式会社は、米国食品医薬品局（FDA）が同社の治験用5価髄膜炎菌ワクチン候補（MenABCWY）の生物製剤承認申請（BLA）を審査用に受理したと発表しました。ファイザーは、10歳から25歳の個人における最も一般的なセログループによる髄膜炎菌疾患を予防するためにMenABCWYを提出しました。さらに、2022年10月17日、GSK plcは、Neisseria meningitidis serogroups A, C, Y, and Wによる侵襲性髄膜炎菌疾患を予防するために、10歳から55歳までの個人向けのメンベオ［Meningococcal（Groups A, C, Y, and W-135）Oligosaccharide Diptheria CRM197 Conjugate Vaccine］の新製法をFDAが認可したことを発表しました。メンベオ・ワン・バイアル製剤は、すぐに使える1回分バイアル製剤となり、ヘルスケア関係者の利便性が向上しました。メンベオ・ワン・バイアル・プレゼンテーションは、まず米国の連邦政府顧客向けに提供され、2023年半ばにはより広い範囲で利用可能となる予定です。したがって、上記の要因から、予測期間中に市場が牽引されることが期待されます。

コンジュゲートワクチンの副作用の少なさが市場成長の妨げになると予想されます。

コンジュゲートワクチンは副作用が少なく、発生しても軽度であり、すぐに治まるという特徴があります。コンジュゲートワクチン接種者の約10%に、硬結、発赤、注射部の腫脹、倦怠感、中程度の発熱、過敏性などの一般的な副作用が認められています。その他の影響も観察されますが、まれであり、すぐに消失します。すべての医薬品やワクチンと同様に、ワクチンやその成分の1つに対してアレルギー反応を起こす危険性がわずかにあります。ほとんどのアレルギー反応は軽度（皮膚の発疹程度）ですが、極めて稀なケースとして、アナフィラキシーショックが起こる可能性があります。したがって、上記の要因から、予測期間中に市場が阻害されることが予想されます。

COVID-19の影響分析

コロナウイルスのパンデミックは、コンジュゲートワクチン市場に中程度の影響を及ぼしています。ブラジルの11州および北部と南部でMenCワクチンの接種が行われました。MenCワクチンの接種率の低下は、COVID-19のパンデミック時に遭遇した困難の1つであり、その結果、ブラジルにおける髄膜炎菌感染率を上昇させる可能性があります。例えば、髄膜炎菌Cコンジュゲートワクチン接種は、調査期間中に全体で1483万2054回接種され、2019年3月から2020年2月までに66.30%、2020年3月から12月までに33.70%が実施されました。COVID-19のパンデミックは、検出された統計的に有意なステップによると、北地域と南地域、およびブラジル11州において、MenCワクチンの接種回数にマイナスの影響を与えました（それぞれ26,98％、41.47％）。

一方、コンジュゲートワクチンの世界市場は、パンデミック時の米国FDA（Food and Drug Administration）によるワクチン承認拡大により、拡大しました。例えば、Pfizer Inc.とBioNTech S.E.は2021年8月、米国食品医薬品局（FDA）が16歳以上のCOVID-19の予防を目的としたCOMIRNATY（COVID-19 Vaccine, mRNA）の生物製剤ライセンス申請（BLA）を認可したと発表しました。2回目投与後6カ月間の有効性・安全性データを含む充実した申請資料が、承認の基礎となりました。以上のような背景から、本市場は影響を受け、今後さらに拡大することが予想されます。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • コンジュゲートワクチンのFDA承認の増加により、市場の成長が見込まれます。
    • 抑制要因
      • コンジュゲートワクチンの副作用の少なさが、市場成長の妨げになると予想されます。
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターの5つの力
  • サプライチェーン
  • プライシング分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • まとめ

第7章 製品タイプ別

  • 一価コンジュゲートワクチン
  • 多価コンジュゲートワクチン

第8章 疾患別適応症別

  • 肺炎球菌
  • インフルエンザ
  • 髄膜炎菌
  • その他

第9章 病原体タイプ別

  • 細菌性
  • ウイルス性

第10章 患者タイプ別

  • 小児
  • 成人

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A（合併・買収）分析

第13章 企業プロファイル

  • GlaxoSmithKline plc.
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Merck & Co. Inc.
  • Fablife
  • SutroVax Inc.
  • Sanofi Pasteur SA.
  • Pfizer
  • Sinovac Biotech Ltd.
  • IDT Biologics GmbH
  • GreenSignal Bio Pharma Limited
  • Taj Pharmaceuticals Limited
  • Bavarian Nordic

第14章 コンジュゲートワクチンの世界市場-DataM

目次
Product Code: DMPH1515

Market Overview

The global conjugate vaccine market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 9.5% during the forecast period (2022-2029).

A conjugate vaccination is a subunit vaccine that uses a strong antigen as a carrier to combine a weak antigen, increasing the immune system's response to the weak antigen. Conjugate vaccines for infectious diseases are available. Some bacteria and viruses have polysaccharide coats that allow them to evade the immune system. An immature immune system can recognize these bacteria when conjugate vaccines are used because these vaccinations connect the unique polysaccharide coats to an organism by eliciting immunity and reaction. Meningococcal vaccinations to prevent meningitis, the Haemophilus influenzae type B (Hib) vaccine, and the pneumococcal vaccine are all examples of conjugate vaccines.

Market Dynamics

Growing approval for the meningococcal conjugate vaccine, increasing key players for developing and introducing vaccines for pneumococcal and meningococcal vaccines, and rising awareness about vaccination programs are the factors to drive the market in the forecast period.

The increasing FDA approvals for conjugate vaccines are expected to drive market growth.

On December 28, 2022, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for its investigational pentavalent meningococcal vaccine candidate (MenABCWY). Pfizer submitted MenABCWY to prevent meningococcal disease caused by the most common serogroups in individuals 10 through 25 years of age. Additionally, on October 17, 2022, GSK plc announced that the FDA had approved a new formulation of Menveo [Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diptheria CRM197 Conjugate Vaccine] for individuals aged 10 to 55 years to help prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W. The Menveo one-vial presentation is now available in a ready-to-use single vial, making it more convenient for healthcare providers. The Menveo one-vial presentation will initially be available to federal customers in the United States, with broader availability expected in mid-2023. Thus, from the above factors, the market is expected to drive in the forecast period.

Fewer side effects of the conjugate vaccine are expected to hamper the market growth.

The conjugate vaccines have had few side effects; when they have occurred, they have been mild and resolved quickly. About 10% of persons getting conjugate vaccines have common side effects such as hardening, reddening, swelling where the injection is given, malaise, moderate fever, and irritability. Other effects have been observed, but they are uncommon and disappear quickly. There is a small risk of an allergic reaction to the vaccine or one of its components, as with all medicines and vaccines. Most allergic reactions are mild (a skin rash and nothing more), but in extremely rare cases, anaphylactic shock can occur. Hence, from the above factors, the market is expected to get hampered in the forecast period.

COVID-19 Impact Analysis

The coronavirus pandemic has moderately impacted the conjugate vaccine market. MenC vaccine doses were given out in 11 Brazilian states and Northern and Southern Brazil. Reduced MenC vaccine coverage is one of the difficulties encountered during the COVID-19 pandemic, and as a result, it may raise meningococcal infection rates in Brazil. For instance, 14,832,054 doses of the meningococcal C conjugate vaccination were delivered overall during the study period, with 66.30% occurring between March 2019 and February 2020 and 33.70% between March and December 2020. The COVID-19 pandemic had a negative effect on the number of MenC vaccine doses delivered in the North and South regions (26,98% and 41.47%, respectively), as well as in the eleven Brazilian States, according to statistically significant steps that were detected.

In contrast, the global market for conjugate vaccines has grown due to the U.S. FDA's (Food and Drug Administration) expanding vaccine approvals during the pandemic. For instance, Pfizer Inc. and BioNTech S.E. announced in August 2021 that the U.S. Food and Drug Administration (FDA) had approved the Biologics License Application (BLA) for COMIRNATY (COVID-19 Vaccine, mRNA), which is intended to prevent COVID-19 in people 16 years of age and older. A thorough submission package, which included six-month efficacy and safety data after the second dose, formed the foundation for the approval. Thus, from the above factors, the market got affected and is expected to boost in the forecast period.

Segment Analysis

Multivalent Conjugate Vaccine segment is expected to hold the largest market share in conjugate vaccine market

The multivalent conjugate vaccine segment accounted for the largest market share in 2021. The multivalent immunogenic conjugates are synthesized using hydrazide chemistry to conjugate mixtures of more than one polysaccharide (at the desired ratio) to at least one carrier protein. Moreover, multivalent conjugate vaccines are cost-effective, improve manufacturing efficiency, streamline the preparation of combined conjugate vaccines, and can also be used to conjugate mixtures of other reagents (peptides, therapeutic agents) to carrier proteins to create therapeutics and reagents compared to monovalent conjugate vaccines. Therefore, it has increased the demand for multivalent conjugate vaccines. Thus, from the above factors, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global conjugate Vaccine market

North America region accounted for the largest market share in 2021. The rise in the prevalence of the infectious disease, the increase in the initiatives by the government, the increasing FDA approvals for the conjugate vaccine, and the rising demand for meningococcal, pneumococcal vaccines and other conjugate vaccines are the factors to drive the market in the forecast period. For instance, On April 24, 2020, the FDA approved a Biologics License Application for the MenQuadfi Meningococcal Conjugate Vaccine to prevent invasive meningococcal disease in people two years older. MenQuadfi is a quadrivalent meningococcal vaccine that uses tetanus toxoid as a protein carrier in the United States. It is available in a ready-to-use liquid formulation, eliminating the need for vaccine reconstitution for healthcare providers. Additionally, On August 31, 2022, the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine to authorize bivalent formulations of the vaccines for use as single booster dose at least two months following primary or booster vaccination. Thus, from the above factors, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the conjugate vaccine market are GlaxoSmithKline plc, Merck & Co. Inc., Fablife, SutroVax Inc., Sanofi Pasteur SA., Pfizer, Sinovac Biotech Ltd., IDT Biologics GmbH, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited and Bavarian Nordic.

On June 08, 2021, Pfizer Inc. announced that the FDA approved PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) to prevent invasive disease and pneumonia caused by the vaccine's 20 Streptococcus pneumoniae (pneumococcus) serotypes in adults 18 years and older.

GlaxoSmithKline plc:

Overview:

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat acute and chronic diseases. The Vaccines business provides vaccines for people of all ages, from babies and adolescents to adults and older people. It has a portfolio of medicines for respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty Products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

Product Portfolio:

Infanrix hexa: Infanrix hexa is a vaccine used to protect babies and toddlers against diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis (polio) and diseases such as bacterial meningitis caused by the bacterium Haemophilus influenzae type b (Hib).

The global conjugate vaccine market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increasing FDA approvals for conjugate vaccines are expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Fewer side effects of the conjugate vaccine are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Supply Chain
  • 5.3. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Monovalent Conjugate Vaccines*
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Multivalent Conjugate Vaccine

8. By Disease Indication

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
    • 8.1.2. Market Attractiveness Index, By Disease Indication
  • 8.2. Pneumococcal*
      • 8.2.1.1. Introduction
      • 8.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Influenza
  • 8.4. Meningococcal
  • 8.5. Others

9. By Pathogen Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type
    • 9.1.2. Market Attractiveness Index, By Pathogen Type
  • 9.2. Bacterial*
      • 9.2.1.1. Introduction
      • 9.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Viral

10. By Patient Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type
    • 10.1.2. Market Attractiveness Index, By Patient Type
  • 10.2. Pediatric*
      • 10.2.1.1. Introduction
      • 10.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Adults

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pathogen Type
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Patient Type

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. GlaxoSmithKline plc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Merck & Co. Inc.
  • 13.3. Fablife
  • 13.4. SutroVax Inc.
  • 13.5. Sanofi Pasteur SA.
  • 13.6. Pfizer
  • 13.7. Sinovac Biotech Ltd.
  • 13.8. IDT Biologics GmbH
  • 13.9. GreenSignal Bio Pharma Limited
  • 13.10. Taj Pharmaceuticals Limited
  • 13.11. Bavarian Nordic

LIST NOT EXHAUSTIVE

14. Global Conjugate Vaccine Market- DataM

  • 14.1. Appendix
  • 14.2. About Us
  • 14.3. Contact Us